September 2020 - Dilemmas in commissioning biological therapies

As we continue with our socially distanced DTB podcasts James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the September issue of DTB. This includes an editorial discussing the challenges facing commissioning organisations when changes to clinical practice or market authorisation have a significant impact on how biological therapies can be used. The editors highlight a study that showed a lack of adherence to guidelines on direct oral anticoagulant dosing in people with atrial fibrillation and renal impairment, and review an article that discusses the risk of seizures with antidepressants. This month's case report involves an Infant with status epilepticus secondary to systemic lidocaine toxicity from topical application. Read the full issue: https://dtb.bmj.com/content/58/9 Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening. Go well and stay well.